Abstract
We report on a 77-year-old patient complaining of abdominal pain who was diagnosed with a gastric mesenchymal tumour with a poor prognosis (high mitotic index, 25% Ki-67 proliferation index and c-kit positive). During surgery, there was instrument-related rupture of the tumour. Coadjuvant therapy with imatinib was initiated. Three weeks later, the patient developed symptoms of congestive heart failure and this led to the discontinuation of imatinib treatment; diuretic treatment was initiated, which led to an improvement in the symptoms. Echocardiography study showed a left ventricle ejection fraction of 55% with an alteration in the relaxation of the ventricle. In the follow-up, there has been no evidence of disease relapse or development of new symptoms.
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects*
-
Antineoplastic Agents / therapeutic use
-
Benzamides
-
Chemotherapy, Adjuvant
-
Female
-
Gastrointestinal Neoplasms / diagnosis
-
Gastrointestinal Neoplasms / drug therapy*
-
Gastrointestinal Neoplasms / surgery
-
Gastrointestinal Stromal Tumors / diagnosis
-
Gastrointestinal Stromal Tumors / drug therapy*
-
Gastrointestinal Stromal Tumors / surgery
-
Heart Failure / chemically induced*
-
Heart Failure / diagnosis
-
Humans
-
Imatinib Mesylate
-
Neoplasm Recurrence, Local / prevention & control*
-
Piperazines / administration & dosage
-
Piperazines / adverse effects*
-
Piperazines / therapeutic use
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Pyrimidines / therapeutic use
-
Rupture
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Pyrimidines
-
Imatinib Mesylate